W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive…
Miasta: Białystok, Gdańsk, Katowice, Lublin i 3 inne miastaWiek: od 18 latSponsor: Genmab A/S
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with…
Miasta: Gdańsk, Katowice, Lublin, Warszawa i 3 inne miastaWiek: od 18 latSponsor: Regeneron Pharmaceuticals Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Miasta: Gdańsk, Warszawa, Wrocław, ŁódźWiek: do 64 latSponsor: Eli Lilly & Co.
W Polsce: ZakończoneNa świecie: RekrutujeFaza III
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic]…
Miasta: GdańskWiek: od 18 latSponsor: Mabxience Research S.L.
RekrutujeFaza II
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Miasta: Gdańsk, Koszalin, Poznań, Przemyśl i 1 inne miastoWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza II/III
Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS)
Miasta: Gdańsk, Katowice, Poznań, Rzeszów i 2 inne miastaWiek: do 17.99 latSponsor: Tg Therapeutics Inc.
RekrutujeFaza III
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer…
Miasta: Gdańsk, Gliwice, Kielce, Siedlce i 1 inne miastoWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
W Polsce: ZakończoneNa świecie: RekrutujeFaza III
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Miasta: Białystok, Gdańsk, Kielce, Siedlce i 1 inne miastoWiek: od 18 latSponsor: Incyte Corp.
RekrutujeFaza III
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Miasta: Białystok, Gdańsk, Kraków, Poznań i 1 inne miastoWiek: od 18 latSponsor: Eli Lilly & Co.
RekrutujeFaza II/III
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Miasta: Gdańsk, Kraków, Warszawa, ŁódźWiek: od 18 latSponsor: Kardigan Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
Miasta: Gdańsk, Poznań, WarszawaWiek: od 18 latSponsor: Novo Nordisk A/S
RekrutujeFaza II
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Miasta: Gdańsk, Koszalin, WarszawaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With…
Miasta: Białystok, Bydgoszcz, Chrzanów, Elbląg i 19 innych miastWiek: od 18 latSponsor: Amgen Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza I/II
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
Miasta: Gdańsk, Kraków, WarszawaWiek: od 18 latSponsor: AstraZeneca AB
RekrutujeFaza III
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Miasta: Gdańsk, Kraków, WrocławWiek: od 18 latSponsor: Sanofi-Aventis Recherche & Developpement
RekrutujeFaza II/III
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
Miasta: Gdańsk, Kraków, Lublin, Warszawa i 1 inne miastoWiek: do 17.99 latSponsor: Argenx
W Polsce: ZakończoneNa świecie: RekrutujeFaza I
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A
Miasta: Białystok, Gdańsk, Katowice, Lublin i 2 inne miastaWiek: 18-64 latSponsor: Novo Nordisk A/S
RekrutujeFaza III
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
Miasta: Białystok, Bydgoszcz, Chojnice, Chorzów i 33 inne miastaWiek: od 18 latSponsor: Alnylam Pharmaceuticals Inc.
RekrutujeFaza III
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Miasta: Chorzów, Gdańsk, Gliwice, Katowice i 8 innych miastWiek: od 18 latSponsor: BioNTech SE
RekrutujeFaza III
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
Miasta: Białystok, Bydgoszcz, Gdańsk, Grudziądz i 11 innych miastWiek: od 18 latSponsor: Dolnoslaskie Centrum Chorob Serca Im. Prof. Zbigniewa…
RekrutujeFaza II
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
Miasta: Gdańsk, Poznań, WarszawaWiek: 10-17 latSponsor: Hoffmann-La Roche
RekrutujeFaza II/III
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard…
Miasta: Gdańsk, Kraków, Lublin, Poznań i 3 inne miastaWiek: od 18 latSponsor: AbbVie Deutschland GmbH & Co. KG
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking…
Miasta: Białystok, Gdańsk, Rybńik, Tuszyn i 1 inne miastoWiek: 18-64 latSponsor: Bristol-Myers Squibb Services Unlimited Company
RekrutujeFaza III
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Miasta: Bydgoszcz, Gdańsk, Gdynia, Katowice i 9 innych miastWiek: od 18 latSponsor: Dizal Pharmaceutical Co. Ltd.
RekrutujeFaza I/II
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer…
Miasta: Gdańsk, Kraków, Poznań, Tomaszów MazowieckiWiek: od 18 latSponsor: BioNTech SE
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
Miasta: Gdańsk, Gliwice, Opole, Poznań i 3 inne miastaWiek: 18-64 latSponsor: Unicancer
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Miasta: Gdańsk, Kraków, Szczecin, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Deciphera Pharmaceuticals Inc.
W Polsce: Rekrutacja zakończonaNa świecie: RekrutujeFaza III
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Miasta: Gdańsk, Katowice, Kraków, OpoleWiek: od 18 latSponsor: Novartis Pharma AG
RekrutujeFaza III
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Miasta: Brzozów, Gdańsk, Kraków, Otwock i 4 inne miastaWiek: od 18 latSponsor: Olema Pharmaceuticals Inc.
RekrutujeFaza I
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Miasta: Bytom, Gdańsk, Gliwice, ŁódźWiek: od 18 latSponsor: Bristol-Myers Squibb Services Unlimited Company